What do systematic reviews say?

RISPERIDONE DEPOT vs RISPERIDONE

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

RISPERIDONE DEPOT vs QUETIAPINE

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

RISPERIDONE DEPOT vs OLANZAPINE

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

CBT plus standard care vs usual care

COMPARISON 1: CBT+ STANDARD CARE showed no clear difference in global state: 1a. Relapse ‐ long term compared with STANDARD CARE ALONE (low certainty).

• Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia 2018 · Cochrane Headline outcomes only
  RR 0.78 [0.61, 1]
  13 studies · 1538 participants
  Low

INTENSIVE CASE MANAGEMENT vs NON‐INTENSIVE CASE MANAGEMENT

The review found no eligible studies for this question.

• Intensive case management for severe mental illness 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

INTENSIVE CASE MANAGEMENT vs usual care

The review found no eligible studies for this question.

• Intensive case management for severe mental illness 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

RISPERIDONE DEPOT vs placebo

The review found no eligible studies for this question.

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

FLUPHENAZINE (ORAL) vs placebo

It is very uncertain whether ORAL FLUPHENAZINE changes global state: Relapse ‐ long termClinical judgement compared with PLACEBO (very low certainty).

• Fluphenazine (oral) versus placebo for schizophrenia 2018 · Cochrane Headline outcomes only
  RR 0.39 [0.05, 3.31]
  2 studies · 86 participants
  Very low

BRIEF FAMILY INTERVENTION vs usual care

BRIEF FAMILY INTERVENTION showed no clear difference in global state ‐ relapse ‐ medium to long term relapse rates (clinical… compared with STANDARD CARE (low certainty).

• Family intervention (brief) for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 0.5 [0.1, 2.43]
  1 study · 40 participants
  Low

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

It is very uncertain whether RISPERIDONE DEPOT changes global state: Relapse (any reason) ‐ long term Number of… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 2.13 [0.84, 5.43]
  1 study · 63 participants
  Very low

RISPERIDONE DEPOT vs ARIPIPRAZOLE

RISPERIDONE DEPOT showed no clear difference in global state: Relapse (any reason) ‐ long term Assessed by 5 blinded… compared with ORAL ARIPIPRAZOLE (low certainty).

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 1.05 [0.83, 1.33]
  1 study · 349 participants
  Low